{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T05:40:54Z","timestamp":1776145254962,"version":"3.50.1"},"reference-count":0,"publisher":"American Association for Cancer Research (AACR)","issue":"11","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>After being pulled from the market 7 years ago, gemtuzumab ozogamicin has been reapproved by the FDA, this time for adults newly diagnosed with acute myeloid leukemia, as well as patients 2 years of age and older with relapsed\/refractory disease. The CD33-targeting antibody\u2013drug conjugate can be given as a single agent or in combination with chemotherapy.<\/jats:p>","DOI":"10.1158\/2159-8290.cd-nb2017-132","type":"journal-article","created":{"date-parts":[[2017,9,21]],"date-time":"2017-09-21T00:25:36Z","timestamp":1505953536000},"page":"1208-1208","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Gemtuzumab Ozogamicin Makes a Comeback"],"prefix":"10.1158","volume":"7","member":"1086","published-online":{"date-parts":[[2017,11,1]]},"container-title":["Cancer Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article-pdf\/7\/11\/1208\/1837879\/1208.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article-pdf\/7\/11\/1208\/1837879\/1208.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,7]],"date-time":"2022-06-07T01:11:42Z","timestamp":1654564302000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article\/7\/11\/1208\/6515\/Gemtuzumab-Ozogamicin-Makes-a-ComebackGemtuzumab"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,1]]},"references-count":0,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2017,11,1]]},"published-print":{"date-parts":[[2017,11,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2159-8290.cd-nb2017-132","relation":{},"ISSN":["2159-8274","2159-8290"],"issn-type":[{"value":"2159-8274","type":"print"},{"value":"2159-8290","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,1]]}}}